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ing or failed femoropopliteal bypass grafts2-14; however,
none have specifically reported on the results of the above-
knee PTFE grafts. Also, most of the data on catheter-
directed thrombolysis of grafts are difficult to interpret
because the results obtained with vein, PTFE, suprain-
guinal, and infrainguinal (above-knee and below-knee)
grafts are frequently reported together.15-18 One of the
commonly quoted studies, the surgery versus thrombolysis
for ischemia of the lower extremity (STILE) study, also
included mixed PTFE and vein grafts, and 40% of the grafts
randomized for lysis never received it because of technical
problems.18 There is also a natural desire to preserve the
original graft in patients who have been treated preferen-
tially with above-knee femoropopliteal bypass grafting with
PTFE to preserve the autogenous vein for future below-
knee bypass grafting. Because the prevailing practice pat-
tern in our community and others, particularly among our
cardiology and interventional radiology colleagues, is to
approach thrombosed femoropopliteal bypass grafts percu-
taneously by using lysis followed by balloon angioplasty
(PTA) of any underlying anastomotic stenoses, we decided
to compare lysis/PTA with the open-repair approach for
failed above-knee femoropopliteal PTFE grafts. Clot
removal from thrombosed PTFE grafts may allow these
Within the last several years, there has been evidence
that the efficacy of polytetrafluoroethylene (PTFE)
femoropopliteal bypass grafts is comparable to that of
autogenous saphenous vein grafts in above-knee locations
in a certain group of patients, for both primary patency and
clinical outcome.1 Similarly, both materials have inherent
properties of bypass grafts in general for stenoses of the
grafts, whether at the inflow or outflow areas or at any
point within the graft. These situations can be the nidus for
potential failure of the graft. Several studies in the last 10
to 15 years have focused on how to treat patients with fail-
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Purpose: Several studies have reported on the outcome of lysis/percutaneous transluminal balloon angioplasty (PTA)
of failed or failing femoropopliteal bypass grafts (FPGs) with mixed results. None of these studies have compared the
results of lysis/PTA versus thrombectomy/open patch repair for failed above-knee polytetrafluoroethylene (PTFE)
FPGs.
Methods: Patients with failed (thrombosed) above-knee FPGs (PTFE, Goretex) during a 10-year period were given the
option to choose between thrombectomy/open patch repair for localized anastomotic short stenosis (≤2 cm; group A,
31 patients) and lysis/PTA or thrombectomy/balloon angioplasty when lysis failed or was contraindicated (group B,
26 patients). The cumulative patency rates were compared by using a Kaplan-Meier life table analysis. All patients
underwent routine color duplex ultrasound scanning/ankle brachial index measurements at 30 days, 6 months, and
every 6 months thereafter.
Results: Demographic and clinical characteristics and indications for intervention were comparable in both groups. The
mean follow-up period was 54.1 and 46.2 months in group A and group B, respectively. There were four perioperative
complications in group A (13%) and seven perioperative complications in group B (27%). Initial technical success and
30-day secondary graft patency rates were 100% in both groups. Overall, 17 of 31 patients (55%) had open grafts, with
no further revisions in group A and six of 26 patients (23%) in group B requiring further revisions (P = .012). Nine
of 31 grafts (29%) failed in group A versus 15 of 26 grafts (58%) in group B (P = .027). The rate of limb loss was com-
parable in both groups (6% vs 12%). The overall cumulative secondary patency rates at 6 months and 1, 2, 3, 4, and 5
years were 100%, 93%, 85%, 72%, 67%, and 62% for group A and 100%, 96%, 88%, 76%, 63%, and 45% for group B (P
= .035). Thirty-five further interventions were needed to maintain graft patency in group B (mean, 1.35; range, 0-3)
versus five further interventions in group A (mean, 0.16; range, 0-1; P < .05).
Conclusion: Thrombectomy/open surgical repair is superior to lysis/PTA (or thrombectomy/balloon angioplasty) for
the treatment of failed above-knee PTFE FPGs with anastomotic stenoses. Therefore, balloon angioplasty should be
reserved for patients who are at high risk for surgery. (J Vasc Surg 2002;35:307-15.)
conduits to be used effectively for long periods when the
underlying stenosis is corrected or bypass grafted.5,8,11,19-
22 None of the earlier published studies compared the
results of thrombolysis/PTA with the results of thrombec-
tomy/open patch repair for failed above-knee PTFE
grafts. This report evaluates the results of both modalities
in a 10-year period.
METHODS
Patients with failed (thrombosed, first failure) above-
knee femoropopliteal bypass grafts (PTFE, Goretex, W.L.
Gore, Flagstaff, Ariz) during a 10-year period (1990-
1999) were given the option to choose between surgical
thrombectomy/open patch repair for localized anasto-
motic short stenoses (a lesion of ≤2 cm; group A, 31
patients) and thrombolysis/PTA or thrombectomy/bal-
loon angioplasty, when thrombolysis failed or was con-
traindicated (group B, 26 patients). During this 10-year
period, 309 above-knee PTFE femoropopliteal bypass
grafts were done, and 96 patients had thrombosed or
failed PTFE grafts (first time failure). Thirty-one of these
patients were treated with other modalities (eg, thrombec-
tomy or lysis only, new bypass grafts for below-knee
popliteal or distal vessels [with autogenous vein]). Eight
other patients were treated conservatively (anticoagula-
tion) for several reasons, such as being at high-risk and
having stable limbs or because they refused further inter-
vention. The indications for the initial surgery were simi-
lar in patients in whom failed bypass grafts developed and
patients whose bypass grafts did not fail: disabling claudi-
cation with failed medical therapy in 56% of patients in
whom failed grafts did not develop versus 55% in patients
with failed grafts. The remaining indications were for rest
pain, trophic changes, or both. The preoperative evalua-
tion included a clinical vascular examination, duplex ultra-
sound scanning, measurement of the ankle brachial index,
and arteriography visualizing the abdominal aorta and
arteries of both lower extremities. All demographic and
clinical characteristics were collected and analyzed.
The degree of acute ischemia was categorized according
to the criteria suggested by the Ad Hoc Committee on the
Reporting Standards of the Society for Vascular Surgery and
the International Society of Cardiovascular Surgery
(SVS/ISCVS).19,20 Only patients with acute ischemia (≤14
days) were included. All patients with inflow or outflow dis-
ease were excluded from this study, including patients with
proximal aortoiliac occlusive disease that necessitated an
intervention or popliteal artery disease that was not local-
ized to 1 to 2 cm from the distal suture line (eg, mid/dis-
tal popliteal artery or poor below-knee runoff [absence of
≥2-vessel runoff] which necessitated a distal below-knee
bypass grafting procedure or other reconstruction).
Surgical thrombectomy/patch angioplasty. Surgical
procedures were performed in an operating room
equipped with a digital fluoroscopy unit. A Fluoroplus
(Phillips Medical System) was used during the first half of
the study, and a special vascular suite equipped with the
International Surgical System (Phoenix, Ariz) was used in
the second half of the study. Graft thrombectomies were
performed in a manner similar to that performed on native
arteries. Our practice was to approach a failed infrain-
guinal PTFE bypass graft at its distal anastomosis, which
allowed an evaluation of the outflow system and identifi-
cation and correction of the most common site for intimal
hyperplasia. The earlier distal incision was opened, and the
distal end of the graft, the distal anastomosis, and the
proximal and distal native artery were dissected free. A
longitudinal incision was then made in the distal end of
the graft within a few millimeters of its distal tip. An initial
extraction with Fogarty balloon embolectomy catheters
was accomplished with extraction of soft clots. This was
followed by Fogarty adherent clot catheters or graft
thrombectomy catheters, as needed, to remove the adher-
ent thrombus that was frequently encountered in artificial
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Fig 1. Kaplan-Meier curve for cumulative primary graft patency for group A versus group B (cumulative patency rates end-
ing at the time of next graft failure [ie, no further intervention]). The range of SEs for patency for group A is 0% to 10.5%,
whereas the range of SEs for group B is 0% to 9.7%.
conduits. Completion retrograde angiography (with an
18-gauge single-wall needle, a 0.035-in guidewire, and a
5F catheter) was performed as a means of delineating the
integrity of the graft and assessing the proximal and distal
suture lines and runoff vessels. Stenosis at the suture line
or just distal to it was corrected by extending the graft
incision distally across its apex and into the recipient artery
until its lumen was no longer narrowed. An autogenous
vein patch was then inserted across the stenosis to widen
the lumen.
In three patients who elected to undergo lysis/PTA,
the grafts could not be catheterized (failed lysis).
Therefore, after operative thrombectomy (via the com-
mon femoral artery), intraoperative balloon angioplasty
was performed with balloon catheters (Boston Scientific,
Watertown, Mass) in 2- to 4-cm lengths and 5- to 8-mm
in diameter, according to the length of the lesion and the
size of the artery as measured by means of intraoperative
arteriograms. The balloons were dilated to 8 to 15 atmos-
pheric pressure for 1 to 2 minutes. After balloon angio-
plasty, pressure gradients, proximal and distal to the
lesions, were measured to assess hemodynamic success.
The pressure gradient was determined by measuring the
proximal femoral artery pressure and the popliteal pres-
sure distal to the lesion. Completion angiography was also
performed. These three patients were kept in group B
because the emphasis of the follow-up data was on the
methods by which the underlying cause of failure was
treated (ie, open patch repair vs PTA).
Early success was achieved when there was no residual
stenosis, as defined radiologically (<30% luminal narrow-
ing) and hemodynamically when the pressure gradient was
abolished or decreased to less than 10 mm Hg. The same
principle was applied to patients treated with open repair or
lysis/PTA.
Heparin (5000 units) was given intravenously before
the thrombectomy, and in all patients, anticoagulation
with warfarin was maintained at an international normal-
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ized ratio of 2 to 3 indefinitely. Antiplatelet therapy (325
mg aspirin daily) was also started within 24 hours after
surgery.
Thrombolysis/percutaneous transluminal balloon
angioplasty. The initial diagnostic arteriogram was per-
formed through the contralateral femoral artery by using
5F catheters. The femoropopliteal grafts were cannulated
by means of either the crossover technique (contralateral
approach) or the ipsilateral femoral artery approach. All
patients, except the last three, received intra-arterial
catheter-directed thrombolysis with urokinase (250,000
units bolus followed by 4000 units/min for 4 hours, then
2000 units/min for as long as 60 hours). The last three
patients were given intra-arterial catheter-directed throm-
bolysis with recombinant tissue plasminogen activator (rt-
PA), 0.05 to 0.1 mg/kg/h for as long as 12 hours. The
rt-PA dosage used in our study was similar to that used in
earlier studies.11 Multi-side hole catheters were used for
lysis. All patients also received heparin (5000 units intra-
venously, followed by 1000 units/h) to maintain an acti-
vated partial thromboplastin time of 1.5 to 2 times the
control. We continued to give heparin until optimal post-
thrombolytic management was achieved. The progression
of lysis was monitored by using color duplex ultrasound
scanning (every 6-12 hours) and angiography every 12
hours until lysis was complete (luminal continuity with
<10% residual clot). Systemic fibrinolytic effects were
monitored by measuring the prothrombin time, activated
partial thromboplastin time, thrombin time, fibrinogen
level, and fibrinogen degradation products. The activated
partial thromboplastin time and the prothrombin time
were maintained at 1.5 to 2 times the control, and the fib-
rinogen level was maintained at more than 100 mg/dL.
The infusion of lytic agents was halted when the fibrino-
gen level fell below 100 mg/dL for a few hours before
resuming the infusion.
PTA was performed as aforementioned for any under-
lying graft suture anastomotic lesions. Proximal lesion
Fig 2. Kaplan-Meier curve for cumulative secondary graft patency for group A versus group B. The range of SEs for
patency for group A is 0% to 11.6%, whereas the range of SEs for group B is 0% to 10.4%.
PTAs were performed via contralateral femoral artery can-
nulation, and distal lesion PTAs were performed via ipsi-
lateral femoral artery cannulation or by means of the
contralateral approach.
After successful lysis, anticoagulation with heparin was
undertaken in all patients, followed by the administration of
warfarin indefinitely, maintaining an international normalized
ratio of 2 to 3 times the control. Patients were also given 325
mg of aspirin daily within 24 hours postoperatively.
Intraoperative and postoperative surveillance.
Follow-up consisted of clinical examinations supple-
mented with duplex scanning examinations and ankle
brachial index measurements at 1, 3, 6, and 12 months
and every 12 months thereafter. Every effort was made to
comply with the reporting standards for lower-extremity
endovascular procedures advocated by the Ad Hoc
Committee of the Joint Council of the SVS/ISCVS.23-25
Perioperative morbidity and mortality were defined as
events occurring within 30 days postoperatively. Graft
patency was assessed by means of duplex scanning exami-
nation, and the clinical/hemodynamic improvements
were judged by means of the clinical examination and the
ankle brachial indices. Arteriograms were obtained when
new symptoms developed, a 15% drop in the ankle
brachial index was detected, or more than 50% stenosis or
occlusion of the graft was documented by means of a
duplex scanning examination.
Statistical analysis. The demographic and clinical
characteristics of both groups were assessed by using the
Pearson chi-square and Fisher exact tests, with a P value
less than .05 considered to be significant. The cumulative
primary and secondary patency rates for both groups were
compared by using the Kaplan-Meier life table analysis.
The cumulative success rates for both groups were then
compared by using the log-rank test and confirmed with
the Wilcoxon test. The method used to calculate the SE
(Tables IV and V) is based on the Kaplan-Meier product-
limit life table survival analysis.
RESULTS
The indications for intervention in group A (open
repair) included 16 patients (52%) with SVS/ISCVS cate-
gory I acute ischemia and 15 patients (48%) with category
II acute ischemia. The indications for intervention in
group B included 16 patients (62%) with category I acute
ischemia and 10 patients (38%) with category II acute
ischemia. The mean duration of ischemia for groups A and
B were similar (3.1 and 3.3 days, respectively; range, 0-14
days). The mean follow-up period was 54.1 days (SE, 2.2
months) and 46.2 months (SE, 3.2 months) for group A
and group B, respectively. The mean age of the grafts from
original insertion to occlusion was 14.3 months for group
A (range, 6-38 months) and 13.5 months for group B
(range, 4-41 months). No patients were lost to follow-up.
Table I summarizes the demographic and clinical char-
acteristics of both groups. The runoff below the distal
anastomosis was comparable in both groups (ie, no signif-
icant mid-distal popliteal artery disease with 2-3 below-
knee vessel runoff). There were no statistically significant
differences between the groups. The grafts could not be
catheterized (failed lysis) in three patients who elected to
undergo lysis/PTA; therefore, they underwent operative
thrombectomy and balloon angioplasty and were included
in group B. Antegrade flow through the graft was re-
established after a mean of 11 hours of lytic infusion
(range, 6-18 hours). However, a complete clot lysis
(obtained in all patients) with visualization of the distal
runoff necessitated 12 to 60 hours of lytic infusion (mean,
26 hours).
At 30 days, 29 of 31 patients (94%) in group A had
improvement in their clinical outcome, as defined by
means of improvement by at least one clinical category,20
versus 24 of 26 patients (92%) in group B (statistically
nonsignificant). In these four patients with failed clinical
improvement, the time between the onset of thrombosis
and intervention was 12 days in one patient, 13 days in
one patient, and 14 days in two patients.
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Table I. Demographic/clinical characteristics: open repair (group A) versus lysis/percutaneous transluminal balloon
angioplasty (group B)
Group A (%) Group B (%)
n = 31* n = 26* P value
Mean age (years, range) 67 (42-79) 69 (45-81) NS
95% CI, 63.74-70.26 95% CI, 65.54-72.46
Sex: male/female 18/13 (58) 16/10 (62) NS
History of smoking 21 (68) 17 (65) NS
Diabetes mellitus 10 (32) 8 (31) NS
Hypertension 23 (74) 18 (69) NS
Hypercholesterolemia 13 (42) 11 (42) NS
Coronary artery disease 17 (53) 15 (58) NS
Proximal anastomotic stenosis 3 (10) 2 (8)
Distal anastomotic stenosis 28 (90) 24 (92)
Indications for surgery
SVS/ISCVS category 1 acute ischemia 16 (52) 16 (62) NS
SVS/ISCVS category 2 acute ischemia 15 (48) 10 (38) NS
*Both groups had similar mid-distal popliteal artery and below-knee 2- to 3-vessel runoff.
NS, No statistically significant differences.
Table II summarizes the perioperative complications
for both groups, with no statistically significant differ-
ences. Two patients in the lysis/PTA group had significant
dissection at the distal suture line (the site of the PTA),
and both were treated with stenting. Two other patients
had anastomotic disruptions, and both underwent open
repair of the disruption. These two patients remained in
the lysis/PTA group for follow-up.
Table III summarizes the early and late graft patency
and limb salvage rates. The initial technical success and the
30-day graft patency rates were comparable for both
groups. One graft from each group thrombosed early, and
both were treated successfully, one with thrombectomy
and one with lysis. Overall, 17 of 31 patients (55%) in
group A had open grafts with no further interventions ver-
sus six of 26 patients (23%) in group B (P = .012). Nine
of 31 grafts (29%) in group A failed versus 15 of 26 grafts
(58%) in group B (P = .027). Of the nine failed grafts in
group A, six were treated by inserting new bypass grafts
with autogenous saphenous veins, and three were treated
conservatively. Of the 15 failed grafts in group B, 11 were
treated by inserting new grafts with autogenous saphe-
nous veins, and four were treated conservatively. The
limb-loss rate was comparable in both groups (6% vs 12%).
Two patients lost limbs in group A, one at 46 months and
one at 59 months, versus three patients in group B, one at
23 months, one at 34 months, and one at 60 months.
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Thirty-five further interventions were needed to maintain
patency in group B (mean, 1.35; range, 0-3) versus five in
group A (mean, 0.16; range, 0-1; P < .05).
Table IV and Fig 1 illustrate a comparison of the
cumulative primary patency rates, beginning after the use
of each of these two alternative methods and ending at the
time of the next graft failure, excluding further interven-
tion in both groups. The cumulative primary patency rates
at 6 months and 1, 2, 3, 4, and 5 years were 97%, 94%,
87%, 83%, 71%, and 58%, respectively, for group A and
92%, 42%, 26%, 26%, 22%, and 22%, respectively, for
group B (P = .0005). The overall cumulative secondary
patency rates at 6 months and 1, 2, 3, 4, and 5 years were
100%, 93%, 85%, 72%, 67%, and 62%, respectively, for
group A and 100%, 96%, 88%, 76%, 63%, and 45%, respec-
tively, for group B (P = .035; Table V, Fig 2).
DISCUSSION
Several authorities advocate the preferential use of PTFE
grafts in certain patients for the above-knee locations, claim-
ing early efficacy equal to that of autogenous saphenous vein
grafts.26-31 Therefore, many of these grafts are presently
inserted in above-knee femoropopliteal bypass grafts.
There have been many attempts in the last 10 to 15
years at identifying the most appropriate method for treat-
ing failed or failing bypass grafts.3-5,8,9,11,14 Options have
included surgical thrombectomy with or without revision,
Table II. Perioperative complications: open repair (group A) versus lysis/percutaneous transluminal balloon angio-
plasty (group B)
Group A (%) Group B (%)
n = 31 n = 26 P value
Deep vein thrombosis of lower extremity 1 0 NS
Myocardial infarction 1 0 NS
Bleeding 1 2 NS
Thrombosis 1 1 NS
Dissection 0 2 NS
Anastomotic disruption 0 2 NS
Deaths 0 0 NS
Total 4 (13) 7 (27) NS
NS, No statistically significant differences.
Table III. Early and late graft patency and limb salvage: open repair (group A) versus lysis/percutaneous transluminal
balloon angioplasty (group B)
Group A (%) Group B (%)
n = 31 n = 26 P value
Early patency
Initial technical success 31 (100) 26 (100) NS
30-day graft patency* 31 (100) 26 (100) NS
Late patency
Open grafts with no further interventions 17 (55) 6 (23) .012
Open grafts with further interventions 5 (16) 5 (19) NS
Failed grafts 9 (29) 15 (58) .027
Limb loss 2 (6) 3 (12) NS
*One graft in each group thrombosed early (perioperatively), and both were treated successfully (thrombectomy/lysis).
NS, No statistically significant differences.
repeat bypass grafting, percutaneous thrombolysis with or
without PTA, and, as a last resort, amputation. Mixed
results have been reported with these various techniques.
When the decision is made to salvage an old PTFE
graft, which may be appropriate if the original location is
above the knee, the proper surgical techniques are critical
in obtaining a good outcome. Surgical thrombectomy of
these grafts is generally performed by approaching the
graft at the distal anastomosis, which allows evaluation of
the outflow system and identification and correction of
the most common site for intimal hyperplasia. The earlier
distal incision is opened, and the distal anastomosis and
the proximal and distal arteries are dissected free. The
graft is then opened with a longitudinal incision to within
a few millimeters of its distal tip. The graft is then
thrombectomized by using balloon catheters that are
passed proximally and distally. This is followed by comple-
tion angiography as a means of evaluating graft patency
and the status of the anastomotic sites and the runoff.
When intimal hyperplasia is noted at or just distal to the
anastomosis, the opening in the graft is extended across its
apex and into the popliteal artery to a point beyond the
disease. Saphenous vein patch angioplasty is used as a
means of closing this opening, and completion angiogra-
phy is performed. When a lesion is limited to the first 1 to
2 cm of the distal anastomosis, a saphenous vein patch
angioplasty to include the distal portion of the graft is a
reasonable option. Acceptable incremental 3-year patency
rates have been reported for this strategy of graft salvage
for failed femoropopliteal above-knee PTFE grafts.19,21
Other options may be used, including performance of a
new autogenous saphenous vein bypass grafting proce-
dure, particularly for below-knee locations.
Alternative therapy includes catheter-directed throm-
bolytic therapy to lyse the clot and reveal the cause of graft
failure, which can be corrected by means of an operative
or endovascular procedure.
Intra-arterial catheter-guided thrombolytic therapy
gives excellent immediate results, with recanalization in
more than 70% of recently thrombosed grafts.10-
12,15,16,32,33 Despite these initial good results, durability is
short-lived.10,12,15,17,34-37 Several studies have reported
that as many as 50% of successfully recanalized grafts reoc-
clude within the first year.10,12,15,17,34-39 Berkowitz12
reported a 72% initial success rate, which decreased to 23%
at 5 years. In this series, even after correcting the underly-
ing causative anatomic defect, and despite indefinite anti-
coagulation and antiplatelet therapy, the 5-year patency
rate in the lysis/PTA group was 45%. In a review of
catheter-directed thrombolysis for arterial and bypass graft
occlusion, Durham and Rutherford38 reported that 50%
of successfully opened grafts re-occluded within 6 months.
Two major prospective randomized trials of throm-
bolytic therapy for lower-extremity ischemia have been
reported.18,40 The results of these two trials were consis-
tent with that of other reports,11 and they confirmed that
patients with acute ischemia of the lower extremity caused
by thrombotic occlusion of either grafts or native arteries
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Table IV. Life table analysis: time to primary patency for 31 patients undergoing open repair (group A) and 26
patients undergoing lysis/percutaneous transluminal balloon angioplasty (group B)* 
Interval (months) Number at-risk at start Number failed Cumulative patency (%) SE (%)
Group A
Entry 31 0 100 0
6 30 1 97 3.2
12 29 1 94 4.4
24 25 2 87 6.2
36 21 1 83 6.9
48 16 3 71 8.7
60 12 3 58 9.9
72 7 3 43 10.5
84 6 0 43 10.5
96 4 0 43 10.5
108 2 0 43 10.5
120 2 0 43 10.5
126 1 0 43 10.5
Group B
Entry 26 0 100 0
6 24 2 92 5.2
12 11 13 42 9.7
24 6 4 26 8.8
36 6 0 26 8.8
48 5 1 22 8.3
60 4 0 22 8.3
72 4 0 22 8.3
84 3 0 22 8.3
96 1 0 22 8.3
*Comparison of the cumulative patency rates beginning after the use of each of the two alternative methods and ending at the time of the next graft fail-
ure, excluding further intervention in both groups (P = .0005).
could be treated effectively with preoperative percuta-
neous lytic therapy. In the STILE trial, lytic therapy was a
successful means of restoring patency in 69% of native
arteries and 81% of the bypass grafts when the lytic agent
was delivered into the clot. There was a reduction in the
extent of planned surgical intervention in 56%. After 6
months’ follow-up, there were fewer amputations in those
patients with acute ischemia randomized to lysis than in
patients undergoing initial surgery (6% vs 18%; P = .061).
One of the major limitations of lysis was the inability to
place a catheter into the clot, which was noted in 41% of
patients with occluded grafts. In the thrombolysis or
peripheral arterial surgery (TOPAS) trial, recanalization
was achieved in 80% of patients, and complete lysis was
obtained in 68% of patients. The amputation-free survival
rate after 6 months’ follow-up was similar in both groups
(72% vs 75%). Thirty-two percent of patients who were
treated successfully with lytic therapy had underlying
lesions that were treated percutaneously, avoiding surgery.
At 1 year, there was a 65% rate of amputation-free survival
in patients undergoing successful lytic therapy, as com-
pared with the 70% rate for patients who underwent
surgery.
Thrombolytic therapy can unmask flow-limiting
lesions that may be the cause of graft thrombosis.
Correction of the underlying flow-limiting lesion is essen-
tial in maintaining long-term graft patency.10,15,18,36,41
However, balloon angioplasty of anastomotic fibrous inti-
mal hyperplasia is characterized by a high recurrence rate,
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reported to range from 51% to 78% at 3 years.10,14,36,42
This is probably related to the limited compressibility of
the hyperplastic lesions.10 Bull et al10 reported that surgi-
cal correction, even when it is technically more challeng-
ing, gives more durable results than percutaneous
angioplasty (1-year patency, 60% vs 31%, respectively).
Similar observations were noted in our experience. Our 5-
year cumulative primary patency rate was 58% for open
repair versus 22% for PTA, and most of the stenotic lesions
that underwent PTA needed further revision to maintain
patency. The patency rate of these grafts might have been
worse in both groups if warfarin sodium had not been
used. Similar findings were noted by Sanchez et al,5 who
reported patency rates of 56% for lysis/PTA and 71% for
surgery (40% of their grafts were PTFE). Our patency
rates were equivalent in the two groups after as long as 4
years of follow-up. This may suggest that the late differ-
ences are caused by disparate durability of patch angio-
plasty versus balloon angioplasty of the anastomotic
lesion, rather than the method of initial thrombus extrac-
tion. However, the low patency rate of these grafts after
balloon angioplasty of these grafts was not associated with
unfavorable limb salvage. Several studies reported that
almost two-thirds of the re-thrombosed grafts were hemo-
dynamically well tolerated and not limb threaten-
ing.10,12,16,18,36,37
The findings of our study reveal that thrombectomy
with open surgical repair is superior to thrombolysis and
PTA for the treatment of failed above-knee PTFE
Table V. Life table analysis: time to secondary patency for 31 patients undergoing open repair (group A) and 26
patients undergoing lysis/percutaneous transluminal balloon angioplasty (group B)
Interval (months) Number at risk at start Number failed Cumulative patency (%) SE (%)
Group A
Entry 31 0 100 0
6 30 0 100 0
12 30 1 93 4.7
24 28 1 85 6.8
36 24 2 72 9.2
48 19 3 67 9.7
60 15 2 62 10.0
72 11 0 62 10.0
84 8 0 62 10.0
96 6 0 62 10.0
108 4 0 62 10.0
120 2 0 62 10.0
Group B
Entry 26 0 100 0
6 25 1 100 0
12 25 2 96 3.8
24 22 3 88 6.4
36 18 3 76 8.6
48 14 4 63 9.8
60 9 2 45 10.4
72 5 0 35 10.2
84 4 0 35 10.2
96 2 0 35 10.2
108 1 0 35 10.2
120 1 0 35 10.2
femoropopliteal bypass grafts. Similar findings, although
in a slightly different but comparable population, were
obtained in the STILE study.18 The authors of that study
concluded that surgical revascularization was significantly
better than thrombolysis in the primary treatment of
lower-extremity bypass grafts. Balloon angioplasty may
continue to have a role in the treatment of patients with
medical contraindications to surgical intervention.
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Dr AbuRahma. I agree with your comments. However, this
series did not include any femoropopliteal bypass PTFE grafts
that were thrombosed early on which did not require any revision
or where there was no underlying lesion. Secondly, the patients
were given the option to choose, after the completion of the
angiogram, with the understanding that if a lesion was found after
the thrombectomy or lysis, it would be approached accordingly.
Dr Kevin G. Burnand (London, United Kingdom). My
granny always told me that 100% or nothing were very bad
results, and I teach medical students that nothing is ever 100%. So
I congratulate you on your results.
Can you tell me, since there was some time after you lysed
the PTFE grafts open, like 4 or 5 years before they went down
again, could you not have treated them at that stage by follow-up
and finding the abnormality and then putting that right?
Dr AbuRahma. In regards to 100% technical success, I would
like to emphasize that there was one patient who had a failed graft
in the first 30 days which was treated with a thrombectomy, and
this gave a secondary technical success of 100%. This 100% was
achieved after a thrombectomy on one graft on each limb of the
study. It was the 30-day results and not immediate technical suc-
cess.
Dr Inam-Ul-Haq (Brooklyn, NY). The PTFE graft that you
had done, do you have any information about the technique that
was employed? Were there any vein patches or vein cuffs that were
used? And if so, did you stratify according to which group fared
better with the lysis and which group fared better with the vein
patch?
Dr AbuRahma. These were conventional above-knee PTFE
grafts, and no cuffs were used in this series.
Dr Anthony J. Comerota (Philadelphia, Pa). We have found
the indication for a femoral above-knee bypass to be exceedingly
limited and, actually, in our experience at Temple, probably have
performed only two in the last 3 or 4 years, because the indica-
tion is most likely related to intermittent claudication. Therefore,
I ask what the indications for a fem above-knee bypass were in
your patients?
You demonstrated that the durability from the time of
implantation to occlusion was in the neighborhood of 13 to 14
months, then the grafts went down. If your patients didn’t have
limb-threatening ischemia when the graft went down, is it worth-
while trying to restore patency to a failed prosthetic graft?
Dr Ali F. AbuRahma. In regards to the indication for using a
PTFE graft for an above-knee location, I would prefer not to
address this since this is a somewhat controversial subject. A sig-
nificant amount of literature has been published over the last 10
years debating this issue. The debate hinges around whether
above-knee bypasses should be done, particularly with PTFE or
other synthetic grafts, and whether it should be used for a primary
indication of claudication. However, the previous surgery for
patients who required a femoropopliteal bypass prior to failure
was around 50% for intermittent claudication. Most of these
patients had stage I and II acute limb ischemia as classified by the
Ad Hoc Committee of the SVS/AAVS.
Dr Richard M. Green (Rochester, NY). I’m a little confused
about the patients that you’re talking about, since every PTFE
graft that goes down doesn’t have an anatomic lesion—some do,
some don’t. Now, were these just those grafts that you were cer-
tain there was a lesion, and, if so, how were you certain until you
lysed or thrombectomized the graft?
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